Resection of thoracic malignancies infiltrating cardiac structures with use of cardiopulmonary bypass

Rawa Arif, Florian Eichhorn, Klaus Kallenbach, Philipp Seppelt, Arjang Ruhparwar, Hendrik Dienemann and Matthias Karck

Abstract

Background: Only few reports exist on malignant thoracic neoplasms that require cardiopulmonary bypass during resection. We aimed to investigate the early and late clinical outcome of these patients.

Methods: Patients with thoracic malignancies that underwent surgery between 2002 and 2014 were analyzed. All patients had cardiopulmonary bypass support during resection. Clinical and perioperative data was retrospectively reviewed for outcome and overall survival.

Results: Fifteen patients (12 female, mean age of 55 ± 15 years, range 24 to 80 years) were identified. Eleven (8 female) were diagnosed with primary thoracic malignomas and four with metastases. Three patients died early postoperatively. Patients diagnosed with sarcoma had a significantly worse outcome than non-sarcoma patients (83.3 ± 15.2 % after 1 year, 31.3 ± 24.5 % after 5 years vs. 83.3 ± 15.2 % after 1 year, 0 ± 0 % after 5 years, p = 0.005).

Conclusions: Malignancies with extension into cardiac structures or infiltration of great vessels can be resected with cardiopulmonary bypass support and tolerable risk. Carefully selected patients can undergo advanced operative procedures with an acceptable 1-year-survival, but only few patients achieved good long-term outcome.

Keywords: Tumor, Sarcoma, Mediastinal tumor, Metastases, Thymus

Background

Thoracic malignancies invading the mediastinum, heart or great vessels are rare and treatment including radical resection challenges oncological therapists. Primary mediastinal neoplasms without invasion into adjacent structures are generally of non-cardiac origin, such as thymoma, lymphoma or neurogenic tumors. Tumors that infiltrate directly into the heart, lung, aorta or vena cava are either primary cardiac malignancies or metastases of distant malignoma. The most common primary cardiac tumors are sarcoma (especially rhabdomyosarcoma or angiosarcoma) and lymphoma [1–6]. Once cardiac structures or great vessels are widely infiltrated, patients are merely treated in only a palliative setting due to an unresectable situation. Nevertheless, very few of these patients might qualify for surgery if local resection seems feasible. In these patients cardiopulmonary bypass (CPB) and cardioplegic cardiac arrest may be necessary in order to enable resection of infiltrated cardiac structures and subsequent reconstruction [7–15]. This interdisciplinary approach requires treatment at a cardiothoracic center and makes meticulous planning within a tumor board mandatory. Nevertheless, CPB-support for resection of advanced cardiothoracic malignancies increases the risk of bleeding from large wound surfaces and may promote a dissemination of tumor cells. Furthermore, immunological responses to extracorporeal circulation bear further risks like lung injury or organ dysfunction [16–19].

The clinical experience with these patients is very limited. Therefore, we report our ten-year single-center experience with patients suffering from thoracic malignoma who require the use of cardiopulmonary bypass during resection.
Methods

Clinical data of patients that underwent surgery at our institution between 01/2002 and 05/2014 was retrospectively analyzed. Fifteen patients (12 female) with a mean age of 55 ± 15 years (range 24 to 80 years) were finally included. All patients had advanced thoracic malignancies and cardiopulmonary bypass support during resection. Two of them underwent combined cardiac surgery for coronary artery bypass grafting (CABG) in addition to tumor resection. All patients were treated in a context of interdisciplinary discussion including both local departments of cardiac and thoracic surgery. Preoperative routine staging included contrast enhanced ECG-gated computed tomography (CT) (Fig. 1) and magnet resonance imaging (MRI) of the chest. Clinical absence of extrathoracic metastasis or active malignant disease was a precondition for surgery. Five patients had diagnostic biopsy prior to operation. Intraoperative transesophageal echocardiography was performed in all patients. The site of cannulation for CPB was selected depending on the tumor localization. Conventional central bi-caval and aortic cannulation was performed in 9 patients, two-stage cannulation of the right atrium (RA) in 1 patient, peripheral cannulation of groin vessels in 5 patients with additional cannulation of internal jugular vein in 1 patient (patient #7). The diagnosis of a malignant tumor was made in 8 patients preoperatively. Final diagnosis was achieved by intraoperative instantaneous section and postoperative histology. Completeness of tumor resection was made by R classification as set by the American Joint Committee on Cancer [20]. All patients were finally debated in an interdisciplinary tumor board concerning postoperative therapies. Adjuvant chemotherapy was advised on an individual basis and was performed in 4 patients. Patient #6 denied adjuvant chemotherapy.

Pre-, intra- and postoperative data was retrospectively analyzed. End points were complications, overall survival and individual outcome. Early events are defined as in-hospital complications. Late events occurred after hospital discharge. After approval of the institutional review board, follow-up was obtained through contact with general physicians or with the patient or family directly. In accordance with the local ethic committee, the requirement of individual patient consent was waived because of the study’s retrospective design and the data collection from routine care. Mean follow-up time was 22 ± 30 months (range 4 to 112). Survival was estimated by use of Kaplan-Meier method. Survival curves were compared using log-rank test. Continuous variables are shown as mean ± standard deviation or as range; categorical data as percentage.

Fig. 1 Preoperative computed tomography scan of patient 11. Carcinoid infiltrating right lung and Vena cava superior
Results

Preoperative data

Eleven (8 female) patients were diagnosed with primary thoracic malignancies and 4 patients (3 female) with metastatic disease infiltrating cardiac structures and/or great vessels (Table 1). Patients with mediastinal metastases were free of local extrathoracic disease before cardiothoracic surgery. Primary tumors of metastatic disease were chondrosarcoma (left heel; infiltration of middle lobe, right lower lobe and left atrium (LA)), malign melanoma (infiltration of left lung (LL) and LA), osteosarcoma (left femur; infiltration of left lower lobe (LLL) and LA) and rectum carcinoma (infiltration of LL and LA).

Patients #1 and #9 were preoperatively diagnosed with coronary artery disease (CAD) and required simultaneous CABG. Patient characteristics, histological tumor diagnosis, operative access, resected structures, R- status, intent of resection approach and follow-up are shown in Table 1.

Operative data

Operation time was 303 ± 182 min (range 140 to 800 min) and CPB time 151 ± 99 min (range 75 to 405 min). Six patients required aortic cross-clamping (53 ± 65 min; range 36 to 173 min). Intraoperative hypothermic levels were set at 31.8 ± 3.8° Celsius (range 20 to 34° Celsius). No patient required total circulatory arrest. Four patients received auto-transfusion with cell-saver blood. Blood cell transfusion requirements measured 3433 ± 5743 ml (range 0 to 19,000 ml). Surgical access to the mediastinum and thoracic cavity was guaranteed through median sternotomy (n = 8), clamshell-incision (n = 4) and lateral thoracotomy (n = 3). Extended pulmonary resections were necessary in 8 cases.

Table 1: Patient characteristics, histological tumor diagnosis, localization, operative access, resected structures, R graduation, therapy aim and follow-up

| Pts No. | Sex | Age | Histological diagnosis and localization | Access         | Resection                                      | Induction, Aim          | Follow-up (month) | Current status | R, Tumor recurrence |
|---------|-----|-----|----------------------------------------|----------------|-----------------------------------------------|-------------------------|-------------------|----------------|------------------------|
| 1       | F   | 80  | Thymoma, anterior mediastinum          | Median sternotomy | Tumor anterior mediastinum                   | None, C                | 0.07              | Dead          | R0                     |
| 2       | F   | 35  | Thymic b-cell Non-Hodgkin lymphoma, anterior mediastinum | Median sternotomy | Tumor anterior mediastinum                   | None, C                | 112.3             | Alive         | R1                     |
| 3       | F   | 54  | Paraganglioma, posterior mediastinum infiltrating LA | Median sternotomy | Ex situ LA, posterior mediastinum, Tumor     | None, P                | 0.67              | Dead          | R?                     |
| 4       | F   | 66  | Intimal sarcoma, MPA and RVOT with tumor thrombus in RUL and RPA | Median sternotomy | MPA, RVOT, tumor thrombus                    | None, C                | 19                | Dead          | R0, lung metastasis   |
| 5       | F   | 58  | Chondrosarcoma metastasis, ML, partial RLL and LA | Right thoracotomy | ML, partial RLL, LA Chemo, P        | 54.8                   | Alive            | R0                     |
| 6       | F   | 49  | Pleomorphic intimal sarcoma, MPA, LPA and LL | Median sternotomy | LL, MPA, LPA None, C            | 21.3                   | Dead              | R1, progressive recurrence in PA |
| 7       | M   | 62  | Thymic carcinoma, VCS and portions within RA | Median sternotomy | Tumor, VCS None, C                | 33.4                   | Dead              | R1, unclear           |
| 8       | F   | 57  | Melanoma metastasis, LL and partial LA | Clamshell | LL, partial LA None, C                | 45.4                   | Alive            | R0, CNS metastasis |
| 9       | F   | 65  | Pleomorphic rhabdomyosarcoma, LA | Median sternotomy | Tumor, partial LA None, C            | 7.2                    | Dead              | R1, local recurrence |
| 10      | F   | 24  | Osteosarcoma metastasis, LLL and partial LA | Left thoracotomy | LLL, partial LA Chemo, C        | 25.8                   | Dead              | Questionable R1, CNS metastasis |
| 11      | M   | 45  | Carcinoid, RL, Aorta, RA and VCS | Clamshell | RL, VCS Chemo, P         | 0.00                   | Dead              | R?                     |
| 12      | F   | 77  | Paraganglioma, Aorta posterior mediastinum | Median sternotomy | Tumor, Aortic adventitia | None, C                | 4.7                | Alive         | R0                     |
| 13      | M   | 40  | Undifferentiated sarcoma (NOS), RL, MPA and LPA | Median sternotomy | Tumor, right thoracotomy | RL, MPA + LPA Chemo, C | 4.3                | Alive         | R0                     |
| 14      | F   | 46  | NSCLC (adenocarcinoma) RL infiltrating LV and MV | Hemi-clamshell | RL, MV + posterior-med. PM Chemo, C       | 3.53                   | Dead              | R1, lung metastasis |
| 15      | F   | 61  | Rectum carcinoma metastasis, LL, LA | Clamshell | LL, partial LA Chemo, C        | 3.2                    | Alive            | R0                     |

Pts., patients; LA, left atrium; RA, right atrium; MPA, main pulmonary artery; RPA, right pulmonary artery; LPA, left pulmonary artery; RVOT, right ventricular outflow tract; ML, middle lobe; RUL, right upper lobe; RLL, right lower lobe; LL, left lower lobe; RL, right lung; VCS, vena cava superior; CNS, central nervous system; C, curative; P, palliative; PM, papillary muscle; NSCLC, non small cell lung carcinoma; MV, mitral valve; PM, papillary muscle
Circulatory support by IABP was performed in patient #1, who simultaneously underwent CABG, and in patients #3 and #4 due to cardiac low output.

Patient #3 suffered from malignant paraganglioma located in the posterior mediastinum with extended infiltration into the left atrium. Complete resection required ex situ tumor removal of the heart with subsequent cardiac auto-transplantation (Figs. 2 and 3): After institution of CPB following bi-caval and ascending aortic cannulation, the heart was explanted. The tumor mass infiltrating the entire left atrial wall was resected respecting a 5 mm margin alongside the atrioventricular junction (Figs. 3 and 4). After resection of the extracardial tumor portion up to the vertebral column, a left neoatrium was created using glutaraldehyd preserved autologous pericardium anastomosed to both pulmonary vein cuffs. Then, the explanted heart was re-implanted suturing the left atrial wall margin to the neoatrium. After auto-transplantation and weaning from CPB with support of an IABP the thorax was left open and covered with a Goretex membrane. The patient was transferred to ICU. After subsequent ECMO implantation the patient died due to multi organ failure on 19th POD.

Complete resection (R0) was pathologically confirmed in 6 cases, 4 patients had tumor-positive resection margins microscopically (R1). R-status remained unclear in 3 patients.

### Postoperative course and outcome

One patient (#11) died intraoperatively due to right heart failure. Two patients died early postoperatively (within 30 days) due to multiorgan failure at POD 1 and 19. All other patients \( n = 12 \) survived the early postoperative course. Overall ventilation time was 2.5 ± 4.9 days (range 0 to 20 d), in hospital survivors 1.3 ± 0.9 days (range 1 to 4 d) respectively. Overall ICU stay was 4.6 ± 5.4 days (range 1 to 20 d), in hospital survivors 3.3 ± 2.5 days (range 1 to 4 d) respectively.

Postoperative early and late morbidity is shown in Table 2. Complications requiring surgical intervention were recurrent pleural effusion (2 patients) and development of hemothorax (1 patient). Two patients received adjuvant chemotherapy, one patient postoperative mediastinal irradiation. Four patients underwent combined radio- and chemotherapy.

Local recurrence of disease emerged in 2 patients. One of these (patient #6) underwent re-surgery within 1 year after primary therapy with R1 resection status. Salvage surgery was performed in a palliative intent to reduce a left atrial tumor mass. Nevertheless, that patient died due to left atrial tumor occlusion and consecutive cardiac output failure during the further postoperative course. 3 patients developed lung and brain metastases and received individual oncological therapy.
Overall actuarial survival was 65 ± 13 % at 1 year and 28 ± 13 % at 5 years (Fig. 5a). Mean Follow-up was 22 ± 30 months (range 4 to 112), six patients are alive at the end of follow-up. Survival in patients with sarcoma histology (80 ± 18 % after 1 year, 20 ± 18 % after 5 years) was found significantly poorer than survival in patients with other dignities (53 ± 17 % after 1 year, 36 ± 19 % after 5 years, \( p = 0.006 \)).

Discussion
There are only few reports of patients undergoing resection of thoracic malignancies with locally advanced invasion into the heart and great central vessels. Molina et al. described an incidence of primary cardiac tumors of 0.002 % in an autopsy series [3]. 75 % of primary cardiac tumors are benign with 2/3 of them being diagnosed as myxoma. One quarter of patients suffers from tumors with sarcoma histology, merely angiosarcoma or intimal sarcoma of great vessels. Unfortunately, most patients were initially found with locally advanced disease and infiltration of adjacent vital structures. Therefore, therapies remained mainly palliative employing conservative chemo- or radiotherapy. Since the early 1990s, first reports favored surgical treatment of malignancies infiltrating cardiac structures by showing improved survival compared to conservative treatment in selected patients [4, 5]. With further improvement of perioperative management including ventilation strategies, circulatory assistance and adjuvant procedures, curative therapy appeared achievable. However, if cardiac structures or great vessels are infiltrated, R0 resection remains challenging and extracorporeal circulation is often required.

Nevertheless, CPB implies several risks. The need of full heparinization may cause excessive bleeding from the surgical field, especially if additional extended lung resection is required. We observed prolonged postsurgical bleeding in 3 of our patients, but only one (patient #6) required redo surgery by videothoracoscopy after development of a hemothorax. Therefore bleeding complications were relatively low in our cohort. Another reported risk of CPB is the possibility of intraoperative tumor spilling, probably supported by venous drainage into the reservoir and re-circulation within the open system of CPB. Four of our patients developed distant metastases, 2 of them after initially complete (R0) resection. One of these suffered from malign melanoma, which is principally associated with a high risk of systemic tumor spread. Unless we did not observe an association with CPB-use and early development of distant metastasis, the avoidance of re-draining suctioned blood from the surgical field into the corporal system might reduce the risk of cell spilling in malignant surgery.

Third, immune modulatory effects are well described and remain a risk for patients undergoing surgery with use of extracorporeal circulation. In addition, patients with lung disease bear a greater risk for pulmonary failure and long-term ventilation after surgery involving CPB [18, 19].

Our cohort includes 8 patients that underwent partial lung resection (\( n = 2 \)) or even pneumonectomy (\( n = 6 \)). Only one of them (patient #11) died intra-operatively due to right heart failure. The other 7 patients showed a median survival of 20 months (range 3 to 55 months) without developing lung or circulatory failure within the early postoperative course. Despite the reported risk for lung failure that can be caused by CPB, none of our patients required tracheotomy or long-term ventilation therapy with an overall ventilation time of 2.5 ± 4.9 days (range 0 to 20), respectively 1.3 ± 0.9 days (range 1 to 4) in hospital survivors. These findings underline the technical feasibility of CPB-usage in operations that include
Table 2 Early and late morbidity and mortality

| Patient No. | Early complications/therapy | Late complications/therapy | Cause of death |
|-------------|----------------------------|----------------------------|----------------|
| 1           | in-hospital death           |                            | MOF            |
| 2           | superficial WHD             | R-CHOEP chemo, Rx          |                |
| 3           | IABP, ECMO, bleeding, in-hospital death |                          | MOF            |
| 4           |                            | lung metastasis, chemo     | Pulmonary failure |
| 5           | right PLE                  | chemo                      |                |
| 6           | haematothorax → VATS        | Rx not possible, palliative chemo declined by patient | cardio-pulmonary failure |
| 7           | PD, PLE                    | Rx                         | unclear        |
| 8           |                            | CNS metastasis, hypothyreoidism under chemo, radiotherapy |                |
| 9           |                            | early recurrent tumor in LA, palliative re-operation with tumor mass reduction | cardiac failure |
| 10          |                            | adjuvant chemo – stop due toxicity, diagnostic partial pulmonary resections, CNS metastasis with bleeding, palliative radiotherapy | CNS death |
| 11          | in-hospital death           |                            | intraoperative right heart failure |
| 12          | intraoperative endograft implantation for Aortic descendens rupture | N. recurrens paresis | |
| 13          |                            | chemo, Rx                  |                |
| 14          |                            | lung metastasis 2 month after discharge | tumor |
| 15          |                            |                            |                |

MOF multi organ failure, WHD wound healing disorder, IABP intra-aortic balloon pump, ECMO extracorporeal membrane oxygenation, PLE pleura effusion, VATS video-assisted thoracic surgery, PD postoperative delirium, CNS central nervous system

Fig. 5 Actuarial overall survival after tumor resection of all patients (n = 15)
partial or total lung resection without encountering an increased risk of pulmonary complications during the postoperative course.

Regarding the low incidence of tumors with only invading the heart and/or great vessels, the cohort we present here is quite heterogenic. In addition, extended cardiothoracic surgery with extracorporeal bypass support represents a high-risk therapeutic approach. Therefore, careful patient selection and intense interdisciplinary discussion within a tumor-board is necessary to point out candidates for surgery. Due to the tumor site and close proximity to vital structures, even surgical salvage procedures can be indicated to prevent secondary complications e.g. tumor-embolism or cardiac tamponade. Such a “palliative” strategy was aimed in 3 of our cases (patients #3, #7 and #11). Nevertheless, all patients were free of extrathoracic malignant foci at time of primary decision.

Preoperative diagnosis of the very malignancy was made in about half of our patients, of whom 5 underwent biopsy. Hence, more interventional or open biopsy prior to operation would have supported multi-modal therapeutic strategies in respect of achieving complete tumor resection e.g. by neoadjuvant therapy, which could lead to tumor mass reduction. Four of our patients underwent systemic induction therapy before tumor resection. In all other patients surgery appeared advisable without induction therapy, either because of rapid clinical deterioration at the time of diagnosis or lack of knowledge of tumor dignity. An example for the former situation is patient #2 (male, 35 years) who initially presented with severe progressive dyspnea at time of first diagnosis. Imaging showed a massive mediastinal mass with compression of the atrial cavities and superior vena cava. In an interdisciplinary debate with respect to the patients’ decision, early surgical resection was indicated rather than primary chemotherapy, even though the latter would have been advised by current guidelines [21]. After macroscopically complete resection (R1, histological diagnosis: Non Hodgkin lymphoma) and immediate relief of his symptoms, chemo- and radiotherapy were administered postoperatively with a favourable outcome. In individual cases, simultaneous functional cardiac disease requiring surgery may influence therapeutic strategy: patient #1 with diagnosis of a thymoma would formally have required induction chemotherapy. However, that patient had to be operated urgently due to concomitant CAD with need of CABG. Therefore, the tumor board advised surgical treatment in favour of induction therapy.

We describe a cohort of patients with locally advanced disease and involvement of multiple organs or, with respect to the heart, multiple cavities. Therefore, intraoperative findings sometimes force to substantially modify the preoperative planned therapeutic strategy: patient #2 was initially planned for resection without CPB. However, due to intraoperative poor hemodynamics, initiation of CPB was required to unload the heart. Local findings in patient #3 necessitated ex vivo resection of the tumor mass from the heart and reconstruction of the left atrium as described by few other authors before [22, 23].

A general principle in oncological surgery is an en bloc, complete tumor removal. The same applies for patients with locally advanced malignancies, even though local technical and functional resectability may force the surgeon to tolerate minimal resection margins or even microscopic tumor residual R1). R0-status could be achieved in 7 of our patients, R1 was found postoperatively in 6 patients. Albeit a very heterogenic group of patients undergoes cardiothoracic surgery for tumor removal with bypass support, acceptable survival-rates can be observed. Park et al. reported a series of 10 patients with an overall median survival of 21.7 months (range 3.2 to 69 months) and 33.3 months (range 3.7 to 69 months) after surgery with incomplete resection in 7 cases. There was no perioperative death observed [12]. In another series of Vaporiyan et al. 19 patients were examined and showed overall 1- and 2-year survival rates of 65 and 45 %, respectively. The authors found incomplete resection in only 4 of their patients but initially included a relatively large collective (n = 8) of patients with simultaneous extrathoracic tumor. Survival in that “palliative” group was poorer but still reached 10.3 ± – 8.6 months [8]. Comparable overall survival were reported by Wiebe et al. with focus on extended pulmonary resection requiring cardiopulmonary bypass support. Cumulative survival in their series was 62 % at 1 year and 53 % at 3 and 5 years, respectively. Patients with histology of sarcoma showed a better outcome than those with non-small cell carcinoma (62.5 % vs 33 % after 1 year) [7]. Analysis of our data showed an actuarial overall survival of 65 ± 13 % at 1 year and 28 ± 13 % at 5 years, which is comparable to other centers. Even though our series as well as literature reports comprise only few patients with rather heterogeneous diseases survival differences depending on histology have been observed. In contrast to Wiebe et al., we found significant poorer survival in patients with sarcoma compared to non-sarcoma. However, Wiebes series contained many patients with non-small lung cancer whereas we also considered other mediastinal malignancies like thymoma, thymic carcinoma or carcinoid tumors with substantially better prognosis [7]. Sole analysis of patients with cardiac sarcoma was recently published by Li et al. In their series of 29 patients, they reported an overall median survival of 17 months, expectably with a significantly better survival for R0 resection status [24]. With regard to our single center results and overview of the current literature, resection of malignancies invasion into the heart or great vessels are extremely rare procedures. Main pathological entities are sarcomas, ensued by secondary tumors with
metastatic lesions invading central mediastinal structures. Surgical resection with bypass support seems feasible with acceptable outcome even in patients with so called “palliative” intent. Complications occur occasionally during CPB-usage and where mainly bleeding events that were manageable by secondary revision. Even patients with incomplete tumor removal might profit in selected cases as well as those patients that are critically limited by mechanical tumor-associated symptoms. However, it is evident that consecutive interdisciplinary discussion to determine oncological therapy is strictly mandatory in all patients.

Conclusions
In conclusion, our review of patients with need of cardiopulmonary bypass support for resection of central tumors shows that the procedure can be performed with tolerable risk and acceptable outcome in carefully selected patients. Certainly, survival is limited but would be presumably worse administering non-surgical therapies. Therefore, well-chosen patients might benefit from surgery even in a palliative intent. Nevertheless, meticulous weighing of conservative and surgical treatment options within a tumor board is mandatory. Thus, definite preoperative diagnosis is of paramount importance and interventional or open biopsy should be performed if imaging not suffices. Patients should be informed that curative resection might be uncertain, in particular in patients suffering from sarcoma.

Abbreviations
C: Curative; CABG: Coronary artery bypass grafting; CAD: Coronary artery disease; CNS: Central nervous system; CPB: Cardiopulmonary bypass; CT: Computed tomography; ECMO: Extracorporeal membrane oxygenation; IABP: Intra-aortic balloon pump; ICU: Intensive care unit; IA: Left atrium; LL: Left lung; LLL: Left lower lobe; LPA: Left pulmonary artery; ML: Middle lobe; MOF: Multi organ failure; MPA: Main pulmonary artery; MR: Magnet resonance imaging; NOS: Undifferentiated sarcoma, not otherwise specified; P: Palliative; PD: Postoperative delirium; PLE: Pleura effusion; RA: Right atrium; RL: Right lung; RLL: Right lower lobe; RPA: Right pulmonary artery; RUL: Right upper lobe; RVOT: Right ventricular outflow tract; VATS: Video-assisted thoracic surgery; VCS: Vena cava superior; WHD: Wound healing disorder.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
RA and FE participated in the design of the study and performed the statistical analysis and drafted the manuscript. PS participated in the design of the study and performed the statistical analysis. KK, AR, MK, HD participated in the design of the study, conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Author details
1Department of Cardiac Surgery, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany. 2Department of Thoracic Surgery, Thoraxklinik Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.

Received: 24 February 2015 Accepted: 19 June 2015 Published online: 25 June 2015

References
1. Silverman NA. Primary cardiac tumors. Ann Surg. 1980;191:127–34.
2. Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12485 consecutive autopsies. Arch Pathol Lab Med. 1993;117:1027–31.
3. Molina JE, Edwards JE, Ward HB. Primary cardiac tumors: experience at the University of Minnesota. Thorac Cardiovasc Surg. 1990;38 Suppl 2:183–91.
4. Burke AP, Cowan D, Virmani R. Primary sarcomas of the heart. Cancer. 1992;69(2):387–95.
5. Putnam Jr JB, Sweeney MS, Colon R, Lanza LA, Frazier OH, Cooley DA. Primary cardiac sarcomas. Ann Thorac Surg. 1991;51(6):906–10.
6. Van der Salim TJ. Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg. 2000;12(2):89–100.
7. Webe K, Baraki H, Macchiarelli P, Haverich A. Extended pulmonary resections of advanced thoracic malignancies with support of cardiopulmonary bypass. Eur J Cardiothorac Surg. 2006;29:571–8.
8. Vapenjak AA, Rice D, Correa AM, et al. Resection of advanced thoracic malignancies requiring cardiopulmonary bypass. Eur J Cardiothorac Surg. 2002;22:47–52.
9. Lang G, Taghavi S, Aigner C, et al. Extracorporeal Membrane Oxygenation Support for Resection of Locally Advanced Thoracic Tumors. Ann Thorac Surg. 2011;92:264–71.
10. Martini N, Yellin A, Ginsberg RJ, et al. Management of non–small cell lung cancer with direct mediastinal involvement. Ann Thorac Surg. 1994;58:1447–51.
11. Pitz CC, Brutel de la Riviere A, van Swieten HA, Westermann CJ, Lammers JW, van den Bosch JM. Results of surgical treatment of T4 non–small cell lung cancer. Eur J Cardiothorac Surg. 2003;24:1013–8.
12. Park BJ, Barcettta M, Bains MS, et al. Surgical management of thoracic malignancies invading the heart or great vessels. Ann Thorac Surg. 2004;78:1024–30.
13. Byrne JG, Leachme M, Agnihotri AK, et al. The use of cardiopulmonary bypass during resection of locally advanced thoracic malignancies. A 10-year two-center experience. Chest. 2004;125:1581–6.
14. Zhang PJ, Brooks JS, Goldblum JR, et al. Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival. Hum Pathol. 2008;39(9):1385–95.
15. Simpson L, Kumar SK, Okuno SH, et al. Malignant primary cardiac tumors: review of a single institution experience. Cancer. 2008;112(11):2440–6.
16. Hill GE, Whitten CW, Landers DF. The influence of cardiopulmonary bypass on cytokines and cell-cell communication. J CardiothoracVascAnesth. 1997;11:1367–75.
17. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1995;55:552–9.
18. Edmunds LH. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1998;66:12–6.
19. Halter J, Steinberg J, Fink G, et al. Evidence of systemic cytokine release in patients undergoing cardiopulmonary bypass. J Extra Corp Technol. 2003;35:272–7.
20. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer (AJCC). AJCC Cancer staging manual. 6th ed. New York, Berlin, Heidelberg. Springer, 2002.
21. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848–57.
22. Kallenberg K, Cremer J, Haverich A. Partial ex situ surgery of the heart. J Thorac Cardiovasc Surg. 2002;123(3):577–8.
23. Colley DA, Rerdon MJ, Frazier OH, Angelici P. Human cardiac explantation and autotransplantation: application in a patient with a large cardiac pheochromocytoma. Tex Heart Inst J. 1985;12:171–6.
24. Li H, Xu D, Chen Z, et al. Prognostic analysis for survival after resections of localized primary cardiac sarcomas: a single-institution experience. Ann Thorac Surg. 2014;97(4):1379–85.

Page 8 of 8